Godavari Biorefineries LimitedQ1 FY27 Results & Financial Update

Management closely monitors rainfall and dam levels in key operational areas of Maharashtra and Karnataka. Recent rains in the last 3-4 weeks have largely addressed initial El Niño-related water availability concerns and improved dam levels compared to a month prior.

Pilot trials for Dimethyl Ether (DME) as an LPG substitute are ongoing, with final results expected by March 2027. The company is also evaluating opportunities in Compressed Bio-Gas (CBG) using available pressmud feedstock in light of new government transition policies.

Management reported strong market demand for green bio-based chemicals from customers in India and overseas, driven by global supply tightness and narrowing price gaps between fossil and green alternatives.

The ongoing E20 rollout and government draft guidelines for E85 and E100, alongside automakers launching flex-fuel vehicles, support long-term demand growth for renewable fuels.

Commissioning of the 200 KLPD grain-based distillery at Sameerwadi expanded total distillery capacity to 800 KLPD during the quarter.

The company is evaluating the addition of a 160 KLPD maize/grain preparation facility within existing infrastructure. If sugarcane juice diversion to sugar is higher, this front-end addition will utilize idle fermentation and distillation capacity without altering total 800 KLPD capacity.

An investment of INR 25 crores is planned to debottleneck bio-based specialty chemical capacity, expected to be completed by early FY28 to achieve INR 240 crores in quarterly revenue.

Bio-based chemicals EBITDA margin expanded to 11.4% from 8.9% in Q1 FY26, aided by debottlenecking benefits and favorable product mix.

Sugar prices have increased over the past few weeks, creating an opportunity for better sugar economics going forward to offset historical static sugar prices against rising cane costs.

Management intends to keep overall debt levels broadly similar or with slight adjustments, avoiding major structural changes to the debt-equity ratio despite ongoing growth investments.

Estimated expenditure of INR 20 crores over the next 2 to 3 years to take the TNBC drug candidate to preliminary efficacy will be funded through internal resources without external capital raises.

Anticipates bio-based chemical revenue to increase to approximately INR 190 crores in Q2 FY27 from INR 169 crores in Q1 FY27.

Targeting a quarterly revenue run-rate of around INR 240 crores for the bio-based specialty chemical business following full implementation of debottlenecking in early FY28.

DME pilot trials are progressing as scheduled with final results expected by March 2027. CDSCO application for preliminary efficacy trials of the TNBC drug candidate was filed in July, with approval anticipated by the end of Q3 FY27.

Taking the drug candidate to preliminary efficacy requires approximately INR 20 crores over 2-3 years, fully covered by internal resources. The integrated model provides optionality to switch between sugar, ethanol, ENA, and biochemicals using sugarcane, maize, and rice feedstocks.

Core focus remains on the integrated biorefinery converting agricultural feedstock into food, fuel, and chemicals, alongside advancing drug discovery. Bio-based chemical revenue is projected to reach INR 190 crores in Q2 FY27.

Chemical margin improvements are viewed as sustainable and growing. The proposed 160 KLPD maize preparation facility will allow utilization of idle sugarcane fermentation and distillation capacity when sugar diversion fluctuates.

Closing sugar inventory at the end of the quarter stood at approximately 65,000 tons, of which an estimated 15,000 to 20,000 tons are tied to long-term contracts and the remainder is open market stock.

Operating cash flows are expected to improve following chemical gross margin expansion and planned debottlenecking. Overall debt structure will remain broadly stable with no major leverage spikes anticipated.

Global supply tightness is driving greater customer interest in bio-based chemicals both domestically and in export markets. Capital allocation near-term prioritizes specialty chemical debottlenecking, front-end maize preparation equipment, and committed R&D spending.